Design Therapeutics (DSGN) Revenue & Revenue Breakdown
Design Therapeutics Revenue Highlights
00
Design Therapeutics Revenue by Period
Design Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | -100.00% |
| 2020-12-31 | $226.00 | -72.90% |
| 2019-12-31 | $834.00 | - |
Design Therapeutics generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Design Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | - | 100.00% |
| 2025-03-31 | - | -100.00% |
| 2024-12-31 | $588.00K | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $838.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | -100.00% |
| 2020-12-31 | $33.00K | 65.00% |
| 2020-09-30 | $20.00K | -35.48% |
| 2020-06-30 | $31.00K | -78.17% |
| 2020-03-31 | $142.00K | - |
Design Therapeutics generated - in revenue during Q2 2025, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Design Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| IMAB | I-Mab | $27.64M | $1.10M |
| KRRO | Korro Bio | $2.27M | $1.09M |
| ALT | Altimmune | $20.00K | $5.00K |
| DSGN | Design Therapeutics | - | - |
| AURA | Aura Biosciences | - | - |
| RCKT | Rocket Pharmaceuticals | - | - |
| DMAC | DiaMedica Therapeutics | - | - |
| ANNX | Annexon | - | - |
| ENGN | enGene | - | - |
| LBRX | LB Pharmaceuticals | - | - |
| GALT | Galectin Therapeutics | - | - |